C
Catherine Barrow
Researcher at Wellington Hospital
Publications - 4
Citations - 144
Catherine Barrow is an academic researcher from Wellington Hospital. The author has contributed to research in topics: Pembrolizumab & Cancer. The author has an hindex of 3, co-authored 4 publications receiving 86 citations.
Papers
More filters
Journal ArticleDOI
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Matteo S. Carlino,Georgina V. Long,Dirk Schadendorf,Caroline Robert,Caroline Robert,Antoni Ribas,Erika Richtig,Marta Nyakas,Christian Caglevic,Ahmed Tarhini,Christian U. Blank,Christoph Hoeller,Gil Bar-Sela,Catherine Barrow,Pascal Wolter,Honghong Zhou,Kenneth Emancipator,Erin Jensen,Scot Ebbinghaus,Nageatte Ibrahim,Adil Daud +20 more
TL;DR: Findings support pembrolizumab monotherapy as standard of care in patients with advanced melanoma, regardless of first- or second-line therapy or PD-L1 status.
Journal ArticleDOI
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Jayesh Desai,Jayesh Desai,Hui K Gan,Hui K Gan,Hui K Gan,Catherine Barrow,Michael B. Jameson,Victoria Atkinson,Andrew Haydon,Michael Millward,Stephen Begbie,Michael P. Brown,Ben Markman,William F. Patterson,Andrew G. Hill,Lisa G. Horvath,Adnan Nagrial,Gary Richardson,Christopher Jackson,Michael Friedlander,Phillip Parente,Ben Tran,Lai Wang,Yunxin Chen,Zhiyu Tang,Wendy Huang,John Wu,Dewan Zeng,Lusong Luo,Benjamin Solomon +29 more
TL;DR: Lifirafenib is a novel inhibitor of key RAF family kinases and EGFR, with an acceptable risk-benefit profile and antitumor activity in patients with B-RAFV600-mutated solid tumors, including melanoma, PTC, and LGSOC, as well as K-RAS–mutated NSCLC and endometrial carcinoma.
Journal ArticleDOI
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
Alexander M.M. Eggermont,Andrey Meshcheryakov,Victoria Atkinson,Christian U. Blank,Mario Mandalà,Georgina V. Long,Catherine Barrow,Anna Maria Di Giacomo,Rosalie Fisher,Rosalie Fisher,Shahneen Sandhu,Ragini R. Kudchadkar,Pablo Luis Ortiz Romero,Inge Marie Svane,James Larkin,Susana Puig,Peter Hersey,Pietro Quaglino,Paola Queirolo,Daniil Stroyakovskiy,Lars Bastholt,Peter Mohr,Micaela Hernberg,Vanna Chiarion-Sileni,Matthew Strother,Axel Hauschild,Naoya Yamazaki,Alexander J C van Akkooi,Paul Lorigan,Clemens Krepler,Nageatte Ibrahim,Sandrine Marreaud,Michal Kicinski,Stefan Suciu,Caroline Robert +34 more
TL;DR: The pembrolizumab treatment after crossover yielded an overall 3-year PFS rate of 32% and a 39% ORR in evaluable patients, but the efficacy was lower in those rechallenged.
Proceedings ArticleDOI
Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Jayesh Desai,Hui K Gan,Catherine Barrow,Michael B. Jameson,Ben Solomon,Victoria Atkinson,Andrew Haydon,Michael Millward,Stephen Begbie,Michael P. Brown,Benjamin Markman,William F. Patterson,Andrew F. Hill,Lisa G. Horvath,Adnan Nagrial,Gary Richardson,Christopher M. Jackson,Michael Friedlander,David Gibbs,Phillip Parente,Jason H. Yang,Lai Wang,Yunxin Chen,Lusong Luo +23 more
TL;DR: BGB-283 was generally well-tolerated during the Phase 1B stage of the study and Antitumor activity was not only observed in subjects with B-RAF V600-mutated solid tumors including melanoma, PTC, and ovarian cancer.